A Sociology of Plasma Proteins – A Technocrat's Perspective

Author:

Farrugia Albert1ORCID

Affiliation:

1. School of Surgery, University of Western Australia Medical School, The University of Western Australia (M509), Perth, Australia

Abstract

This commentary addresses the article “Toward a Sociology of Plasma Products” by Holloway and Grundy in this issue of the International Journal of Social Determinants of Health and Health Services. The program of research proposed by the authors positioning the medico-industrial field of plasma products within a sociological context is supported, this being an endeavor which has not been attempted previously. I seek to augment Holloway and Grundy's proposed approach through some additional insights which are the result of over forty years of personal commitment in the field. Holloway and Grundy's proposed areas of engagement involving the products, the recipients, the donors and the governance of the systems binding these together is widened through an examination of additional technological factors that have shaped the field. These factors include the influence of the medical industry, the role of patient groups, the continuing controversy on the sourcing of plasma raw material, and the roles of different governance models. Converging these factors with Holloway and Grundy's proposed program should enhance its capacity to develop a framework for understanding the dynamics within this complex and unique sector. The concepts developed in both articles will assist stakeholders to develop a societal framework for the provision of these essential medicines.

Publisher

SAGE Publications

Reference22 articles.

1. The legacy of haemophilia: Memories and reflections from three survivors

2. Promising Growth and Investment in the Cell Therapy Industry during the First Quarter of 2012

3. Becker Z. Costing $3.5M, first hemophilia B gene therapy wins FDA approval. Published November 23, 2022. Accessed April 18, 2024. https://www.fiercepharma.com/pharma/csl-and-uniqures-hemophilia-b-gene-therapy-scores-approval-35-million-price-tag.

4. European Commission. Commission welcomes European Parliament’s adoption of the European Health Data Space and regulation on substances of human origin. European Commission - European Commission. Published April 24, 2024. Accessed April 26, 2024. https://ec.europa.eu/commission/presscorner/detail/en/IP_24_2250.

5. A Brief History of Evidence-Based Medicine (EBM) and the Contributions of Dr David Sackett

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3